Fig. 1 · Structure

Documents & Downloads

Divalproex sodium

Cat. No. A10321 CAS 76584-70-8
Divalproex sodium consists of a compound of sodium valproate and valproic acid in a 1:1 molar relationship in an enteric coated form. It is used in the United Kingdom, Canada, and United States for the treatment of the manic episodes of bipolar disorder.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Divalproex sodium increased histone H3 acetylation in ataxin-3-expressing HEK293 cells at 0.3 mmol/L after 24 h. This cellular result is consistent with HDAC inhibition; it does not establish direct enzyme potency or isoform selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Divalproex sodium Research Summary

This section summarizes 3 in vitro studies of Divalproex sodium from 1 published reference. In vitro models include CHO cells stably expressing expanded ataxin-3.

Divalproex sodium In Vitro Studies

In expanded-ataxin-3 CHO cells, divalproex sodium improved the PrestoBlue viability readout relative to DMSO at 100–1000 μmol/L after 2 or 24 h. High-concentration vehicle effects complicate the 2 h result. In a separate HEK293 model, 10 μmol/L for 24 h did not significantly reduce expanded-ataxin-3 aggregation. These model-specific responses do not demonstrate disease modification. [1]

Histone H3 acetylation in ataxin-3-expressing HEK293 cells

Cell-based study · HEK293 cells transiently expressing normal ataxin-3 (15Q) or expanded ataxin-3 (77Q) [1]

Acetylated H3 normalized to total H3 increased significantly after 24 h versus DMSO. Earlier increases were trends without significance. This is a cellular pharmacodynamic endpoint, not a direct HDAC activity assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Acetylated histone H3 / total histone H3Western blot densitometry 24 h: P < 0.05 in both models; 6 h: P = 0.1 (15Q), P = 0.07 (77Q); 12 h: P = 0.1 in both models; n = 3 independent experiments; error bars SEM[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.3 mmol/L
Exposure duration
6, 12 and 24 h; treatment initiated 48 h after transfection
Method
Addition to cultured cells
Vehicle
DMSO; DMSO-only controls
Reported limits
Final DMSO percentage and tested lot analytical identity are not specified in the retrieved text.
Methods and source locations

Compound reported in the paper: Divalproex sodium; Compound label in the paper: Divalproex

Reported findings apply to the study material and these cell models; they do not establish Adooq lot performance.

Section 3.1; Figure 1; Sections 2.1, 2.2, 2.4, 2.7

Acetylated histone H3 / total histone H3: Western blot; total H3 and ataxin-3 controls; Student t-test — Section 3.1; Figure 1 image and caption; Sections 2.4, 2.7

Viability response in expanded-ataxin-3 CHO cells

Cell-based study · CHO cells stably expressing expanded ataxin-3 (77Q) [1]

PrestoBlue fluorescence supported a viability benefit at 100–1000 μmol/L relative to DMSO after 2 or 24 h. At 2 h, the highest concentration also reduced signal relative to untreated cells, with a greater reduction in the DMSO control. Vehicle effects limit interpretation of protection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PrestoBlue fluorescence normalized to untreated cells or DMSOResazurin-based metabolic viability readout Benefit reported at 100–1000 μmol/L at 2 and 24 h; n = 3 independent experiments; error bars SEM; Figure 5 uses **P < 0.01 and ***P < 0.001[1]

Literature-Reported Treatment Conditions

Treatment concentration
Reported rescue range: 100–1000 μmol/L; a wider dilution series is plotted in Figure 5
Exposure duration
2 and 24 h
Method
Addition to cultured cells
Vehicle
DMSO; DMSO-only controls
Reported limits
Final DMSO percentage and tested lot analytical identity are not specified in the retrieved text.
Methods and source locations

Compound reported in the paper: Divalproex sodium; Compound label in the paper: Divalproex

Reported findings apply to the study material and these cell models; they do not establish Adooq lot performance.

Section 3.5; Figure 5; Sections 2.1, 2.2, 2.6, 2.7

PrestoBlue fluorescence normalized to untreated cells or DMSO: PrestoBlue fluorescence; untreated and DMSO comparators; two-way ANOVA — Section 3.5; Figure 5A–D and caption; Sections 2.6, 2.7

No significant reduction of expanded ataxin-3 aggregation

Cell-based study · HEK293 cells expressing expanded ataxin-3 (148Q), with normal ataxin-3 (15Q) as comparator [1]

Divalproex sodium did not significantly reduce SDS-resistant expanded ataxin-3 aggregates relative to DMSO or untreated controls under the reported conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SDS-resistant ataxin-3 aggregate signalFilter trap assay No significant difference versus DMSO or untreated cells (ns); n = 4 independent experiments; error bars SEM[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μmol/L
Exposure duration
24 h, as specified in Figure 3 caption
Method
Addition to cultured cells
Vehicle
DMSO; DMSO-only controls
Reported limits
Final DMSO percentage and tested lot analytical identity are not specified in the retrieved text.
Methods and source locations

Compound reported in the paper: Divalproex sodium; Compound label in the paper: Divalproex

Reported findings apply to the study material and these cell models; they do not establish Adooq lot performance.

Section 3.3; Figure 3; Sections 2.2, 2.5, 2.7

SDS-resistant ataxin-3 aggregate signal: Filter trap assay; normal-repeat and expanded-repeat constructs; DMSO and untreated controls; Student t-test — Section 3.3; Figure 3 image and caption; Sections 2.5, 2.7

Specifications

Manufacturer Adooq Bioscience
CAS Number 76584-70-8
Formula C8H16O2.C8H15O2.Na
Molecular Weight 310.41
Synonyms Valproate semisodium
SMILES
CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 61 mg/mL (196.51 mM)
Water 61 mg/mL (196.51 mM)
Ethanol 61 mg/mL (196.51 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Divalproex sodium Research References

  1. [1] Wang ZJ, Hanet A, Weishäupl D, et al. Divalproex sodium modulates nuclear localization of ataxin-3 and prevents cellular toxicity caused by expanded ataxin-3. CNS neuroscience & therapeutics (2018). PMID: 29318784 DOI: 10.1111/cns.12795 Source material

Added to your cart

View Cart Checkout
Loading...